Effective Treatments for Pyridoxine-Dependent Epilepsy in Children
Researchers examined the effectiveness of different treatment approaches for pyridoxine-dependent epilepsy (PDE), a rare condition caused by genetic mutations.
This hub covers epilepsy genetics: how gene changes can contribute to seizures (often in children). We translate studies on testing, results like VUS, and what findings may change for care.
No. It’s common in pediatrics, but adults can benefit from genetic testing, too, especially with unclear diagnosis or family history.
Sometimes. For certain conditions, results can guide medication choice, diet therapies, or referral decisions.
It usually means “not enough evidence yet.” It shouldn’t be treated as a definite cause, but it can be reclassified over time.
Not necessarily. Testing can miss some variants, and new gene links are still being discovered.
Researchers examined the effectiveness of different treatment approaches for pyridoxine-dependent epilepsy (PDE), a rare condition caused by genetic mutations.
Researchers studied how certain genetic variations in the ADORA2A gene might affect how children with epilepsy respond to two medications: valproic acid and oxcarbazepine.
Researchers studied the relationship between specific genetic variations in the SCN1A gene and resistance to sodium valproate, a common epilepsy medication, in children.
Researchers focused on understanding the role of a specific gene called USP25 in genetic generalized epilepsy.
Researchers studied how cognitive function is affected in children with epilepsy, particularly those who might need surgery.
Researchers conducted a study to explore the use of a secure digital tool for sharing videos of suspected seizures in children.
Researchers conducted a study to understand how effective first-line antiseizure medications (ASMs) are for children newly diagnosed with epilepsy.
Researchers investigated the effects of using preventive anticonvulsant medications in patients who experienced cardiac arrest and were treated with mild hypothermia.
Researchers investigated the use of intravenous (i/v) levetiracetam (LEV) as a first-line treatment for patients experiencing non-convulsive status epilepticus (NCSE), a serious condition where seizures occur without noticeable convulsions.